Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 36Carcinoma, Non-Small-Cell Lung 36Multiple Myeloma 26Breast Neoplasms 26Glioma 23Carcinoma, Renal Cell 22Pancreatic Neoplasms 21Melanoma 21Glioblastoma 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Ovarian Neoplasms 19Urinary Bladder Neoplasms 18Lymphoma 18Colorectal Neoplasms 18Triple Negative Breast Neoplasms 15Oropharyngeal Neoplasms 15Mouth Neoplasms 15Brain Neoplasms 15Fallopian Tube Neoplasms 13Carcinoma, Hepatocellular 13Carcinoma 13Laryngeal Neoplasms 12Astrocytoma 12Lymphoma, Follicular 11Leukemia, Myeloid, Acute 11Sarcoma 10Neuroblastoma 10

Interventions

Nivolumab 2cabozantinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡